H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Barinthus Biotherapeutics (BRNS) to $3 from $5 and keeps a Buy rating on the shares after the company announced a corporate restructuring. The firm has reduced the probability of approval for VTP-300 from 45% to 15%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Barinthus Biotherapeutics Restructures to Focus on Immunotherapy
- Barinthus announces strategic focus in I&I, provides financial update
- Barinthus Biotherapeutics Appoints New Chief Scientific Officer
- Barinthus CSO Nadege Pelletier to depart, Geoffrey Lynn to succeed
- Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results